摘要
目的探讨CMTM2在人睾丸肿瘤组织中的蛋白表达及其临床病理学意义。方法运用组织芯片技术、免疫组织化学方法检测CMTM2在人睾丸肿瘤组织和正常组织中的表达。结果15例正常人睾丸对照组中11例（733％）CMTM2蛋白表达为阳性；26例精原细胞瘤中17例（65．4％）CMTM2蛋白表达为阳性；7例畸胎瘤中4例（57．1％）CMTM2蛋白表达为阳性；12例胚胎癌中3例（25O％）CMTM2蛋白表达为阳性；10例卵黄囊瘤中4例（400％）CMTM2蛋白表达为阳性。胚胎癌、卵黄囊瘤组与正常人睾丸对照组相比较，两组间具有显著性意义（P〈0．05）。而精原细胞瘤实验组以及畸胎瘤实验组与正常人睾丸对照组相比较，没有显著性差异（P〉0．05）。结论CMTM2蛋白在胚胎癌、卵黄囊瘤中的表达水平较正常对照睾丸组织显著降低，CMTM2可能为睾丸肿瘤候选的抑癌基因。
Objective To investigate the expression of CMTM2 in human testicular cancer tissues and its clinicopathological significance. Methods The expressions of CMTM2 in testicular cancer tissues and normal testis tissues were detected by immunohistochemistry. Results Immunohistochemistry analysis showed that 73.3% （11/15） of normal testis tissues, 65.4%（17/26） of seminoma tissues, 57.1%（4/7） of teratoma tissues, 25.0%（3/12） of embryonal carcinoma tissues, and 40.0% （4/10） of yolk sac tumor tissues had positive expression of CMTM2. The expression levels of CMTM2 in embryonal carcinoma tissues and yolk sac tumor tissues were significantly lower than that of the normal control （P〈0.05, respectively）, but those of seminoma tissues and teratoma tissues had no significant differences （P〉0.05,respectively）. Conclusion Low expressions of CMTM2 in embryonal carcinoma tissues and yolk sac tumor tissues suggested that CMTM2 might be a cancer suppressor candidate gene.
出处
《中国男科学杂志》
CAS
CSCD
2011年第3期3-6,共4页
Chinese Journal of Andrology
基金
国家自然科学基金（30972994）
关键词
睾丸肿瘤
组织芯片
免疫组织化学
testicular cancer
tissue microarray
inmunohistochemistry
